Tag Archives: NKTR

Top 5 Undervalued Stocks To Own For 2019

Willamette Valley Vineyards (NASDAQ: WVVI) is a nano-cap winery located in Turner, Oregon. The company produces various mid end, premium, and ultra-premium wines including the Pinot Noir, Chardonnay, Pinot Gris, Ros茅 and Riesling varieties. We usually cover tech stocks but we are big fans of wine and even bigger fans of undervalued stocks; WVVI certainly fits the bill for both. WVVI has enjoyed tremendous average sales and EBITDA growth of 12.8% and 16% respectively for the past 3 years. During the same time period, investors have been met with a modest stock growth of 23.75% from $6.10 to $8 currently. With a market cap of only $40 million and a fair P/E of 22, we believe there is still undiscovered potential for this profitable company and its drought-free wine business.

The Economy of Wine

In the past 6 years, United States wine consumption has seen healthy growth from 336.3 million 9 liter cases in 2010 to 383.9 million 9 liter cases in 2015, This resulted in the total retail value of wine increasing from $46.5 billion in 2010 to $55.8 billion in 2015, a significant 20% growth rate. According to a recent report by goodfruits.com, this growth trend continued in 2016 as “September U.S. wine sales rose from $3.3 billion to $3.7 billion, helping set an annual pace to boost the industry’s overall retail value for the 11th consecutive year”. The prior three 5 year periods has seen total retail value increase by 8.8 billion (2001-2005), 5 billion (2006-2010) and 7.2 (2011-2015). We expect the wine market retail value to grow 1.5% (average growth of the last 3 years) in 2017 and surpass $62 billion by 2020. This growth in wine consumption is further fueled by the inauguration of Donald Trump, whose victory has left many oppositions drinking to a stupor. Under these conditions, we believe specialize vineyards like WVVI are going to earn steady and growing profits for years to come.

Top 5 Undervalued Stocks To Own For 2019: Foamix Pharmaceuticals Ltd.(FOMX)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Press coverage about Foamix Pharmaceuticals (NASDAQ:FOMX) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Foamix Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.4298608245084 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Top 5 Undervalued Stocks To Own For 2019: PJT Partners Inc.(PJT)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on PJT Partners (PJT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Undervalued Stocks To Own For 2019: NovoCure Limited(NVCR)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Novocure (NVCR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Brian Feroldi]

    After the company announced details of its phase 3 INNOVATE-3 trial at theAmerican Society of Clinical Oncology (ASCO) annual meeting, shares ofNovoCure (NASDAQ:NVCR), a red-hot medical device companyfocused on cancer, fell as much as12% in early morning trading today. Shares were down about 10% as of 10:30 a.m. EDT.

  • [By Ethan Ryder]

    NovoCure (NASDAQ:NVCR) Director Gabriel Leung sold 80,000 shares of the firm’s stock in a transaction on Wednesday, May 16th. The stock was sold at an average price of $28.83, for a total value of $2,306,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

  • [By Chris Lange]

    Novocure Ltd. (NASDAQ: NVCR) announced results from its Phase 3 INNOVATE trial of TTFields in platinum-resistant ovarian cancer. There were no major surprises, except study size is larger than some investors expected, which is not concerning. INNOVATE-3 is set to start later this year and as previously announced will enroll patients with recurrent platinum-resistant ovarian cancer.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on NovoCure (NVCR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 5 Undervalued Stocks To Own For 2019: Nektar Therapeutics(NKTR)

Advisors’ Opinion:

  • [By Todd Campbell]

    Surprising and market-moving information often comes out of the annual American Society of Clinical Oncologists (ASCO) meeting, and so far, ASCO18 hasn’t disappointed. From bluebird bio’s (NASDAQ:BLUE) great-but-not-good-enough results in multiple myeloma to Loxo Oncology’s (NASDAQ:LOXO) stellar results in RET-fusion cancers to Nektar Therapeutics (NASDAQ:NKTR) head-scratching data,here are some quick takes on the data released this weekend.

  • [By Stephan Byrd]

    TRADEMARK VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Trading Down 7%” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at www.tickerreport.com/banking-finance/3362849/nektar-therapeutics-nktr-trading-down-7.html.

  • [By Ethan Ryder]

    Nektar Therapeutics (NASDAQ:NKTR) has been given a consensus recommendation of “Buy” by the fifteen ratings firms that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $85.09.

Top 5 Undervalued Stocks To Own For 2019: LightPath Technologies, Inc.(LPTH)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) shares rose 14.1 percent to $3.65 in the pre-market trading session after reporting 2017 year-end results.
    LightPath Technologies, Inc. (NASDAQ: LPTH) rose 13.3 percent to $2.43 in pre-market trading after reporting a third-quarter earnings beat.
    MYnd Analytics, Inc. (NASDAQ: MYND) rose 10.5 percent to $3.49 in pre-market trading. MYnd Analytics reported a Q2 net loss of $2.7 million on revenue of $459,900.
    SORL Auto Parts, Inc. (NASDAQ: SORL) shares rose 8.4 percent to $5.68 in pre-market trading after reporting upbeat Q1 results.
    Famous Dave's of America, Inc. (NASDAQ: DAVE) shares rose 7.7 percent to $8.40 in pre-market trading after the company reported upbeat earnings for its first quarter on Monday.
    Xenon Pharmaceuticals Inc. (NASDAQ: XENE) rose 7.5 percent to $6.45 in pre-market trading after the company presented XEN901 Phase 1 clinical update and XEN1101 TMS pharmacodynamic Phase 1 data.
    Mimecast Ltd (NASDAQ: MIME) rose 6.5 percent to $43.50 in pre-market trading following a first-quarter sales beat.
    Boxlight Corporation (NASDAQ: BOXL) rose 6 percent to $12.50 in pre-market trading after surging 77.44 percent on Monday.
    Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares rose 6 percent to $26.05 in pre-market trading after climbing 3.58 percent on Monday.
    PPDAI Group Inc. (NASDAQ: PPDF) rose 4.7 percent to $7.20 in pre-market trading following Q1 results.
    Xunlei Limited (NASDAQ: XNET) rose 4.1 percent to $13.88 in pre-market trading after gaining 2.54 percent on Monday.
    Valeant Pharmaceuticals International, Inc. (NYSE: VRX) shares rose 4.5 percent to $21.73 in pre-market trading. Mizuho upgraded Valeant from Neutral to Buy.
    Bovie Medical Corporation (NYSE: BVX) rose 4.1 percent to $3.80 in pre-market trading after reporting a first-quarter sales beat.
    Myomo, Inc. (NYSE: MYO) rose 3.4 percent to $4.00 in pre-market trading after jumping 23.25 percent o
  • [By Joseph Griffin]

    Headlines about LightPath Technologies (NASDAQ:LPTH) have been trending somewhat positive on Monday, Accern Sentiment reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. LightPath Technologies earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the technology company an impact score of 46.9867601112654 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Crispr Therapeutics: Assessing The Recent Capital Financing

The reason why the growth stocks do so much better is that they seem to show gains in value in the hundreds of percent each decade. In contrast, it is an unusual bargain that is as much as 50 percent undervalued. The cumulative effect of this simple arithmetic should be obvious. – Philip Fisher (the Father of Growth Investing)

On Jan 05, 2018, the share price of Crispr Therapeutics (NASDAQ:CRSP), a bioscience focusing on gene-editing and CAR-T to treat serious conditions such as cancers and genetic diseases, continued its rally. The stock added another $2.90 (over 12% profits) to value at $26.81 for the said trading session. Since we recommended the company on Nov. 27, 2017 (just over a month) to subscribers of Integrated BioSci Investing, the stock added another $7.26 (or 37% in capital appreciation). This robust run-up is interesting because, on Jan. 04, 2018, the company announced that the 5M additional common shares issued on Jan 03 will be priced at $22.75.

Figure 1: Crispr stock chart. (Source: Stockcharts).

At Integrated BioSci Investing (IBI), we have much success in finding robust performers. For instance, Nektar Therapeutics (NASDAQ:NKTR) appreciated over 200% for subscribers. Exelixis Inc procured over 50% profits. In this report, we’ll assess the ramifications of the recent financing and to reaffirm the investment thesis on Crispr.

Fundamentals Analysis

Back in 2017, there were several stellar medical breakthroughs that have ramifications that can be as far reaching as the introduction of chemotherapy more than a decade prior. Accordingly, the US FDA approved Yescarta (a CAR-T indicated for the treatment of non-Hodgkin lymphoma). The said molecule was innovated by Kite Pharma (NASDAQ:KITE) – a firm acquired by Gilead Sciences(NASDAQ:GILD). Moreover, the agency also approved the first gene therapy, Luxturna (voretigene neparvovec-rzyl), a molecule innovated by Sparks Therapeutics (NASDAQ:ONCE). It is a one-time treatment for patients afflicted with biallelic RPE65 mutation-associated retinal dystrophy.

In the midst of the aforesaid favorable regulatory environment for medical breakthroughs, the Switzerland-based company, Crispr Therapeutics is also brewing a revolutionary method of treating cancers and rare genetic diseases. As follows, CRISPR/Cas9 is a form of gene-editing currently being investigated in various conditions (as shown in the enriched pipeline in figure 2). The company also has a gene-editing enhanced form of CAR-T in development for various cancers. Of most interest is the lead molecule, CTX-001 (also a gene-editing therapeutic) that can be potentially used for the management of serious blood disorders: beta-thalassemia and sickle cell disease (SCD).

Figure 2: Therapeutic pipeline. (Source: Crispr).

Final Remarks

As alluded, Crispr recently issued another 5M common shares at the price of $22.75. The company also granted the underwriters a 30-day option to purchase up to 750K of its common shares. The expected gross proceeds from this offering are roughly $113.75M (excluding any exercise of the underwriters option to purchase additional shares). Moreover, the offering is expected to close on Jan. 09. The company employed Goldman Sachs (NYSE:GS), Piper Jaffray (NYSE:PJC), Barclays Capital (NYSE:BCS), and Guggenheim Securities as joint book-running managers for the said offerings. We strongly believe that the aforesaid capital financing is both strategic and prudent, as substantial capital (in the ballpark of over a billion dollars) is needed to fund a molecule from bench research to commercialization. With the share price appreciating, it is wise that the firm issued new shares to strengthen its capital for further pipeline innovation. There is an in-depth Integrated BioSci version of this research, which is available in advanced to subscribers of Integrated BioSci Investing.

Authors Notes: Were honored that you took the time out of your busy day to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Dr. Tran BioSci analyst, Ngoc Vu, and other PhDs), Integrated BioSci Investing (IBI) marketplace research is delivering stellar returns since inceptions. To name a few, Nektar Therapeutics (NASDAQ:NKTR) procured more than 210% profits; Spectrum Pharmaceuticals (NASDAQ:SPPI) delivered over 180% gains; Kite Pharma netted 82%. Exelixis Inc (NASDAQ:EXEL) earned greater than 50% capital appreciation. Our secret sauce is extreme due diligence coupled with expert data analysis. The service features a once-weekly exclusive in-depth Integrated BioSci Alpha-Intelligence article (in the form of research, reports, or interviews), daily individual stocks consulting, and model portfolios.

Notably, well increase our price soon. SUBSCRIBE to our marketplace research now to lock in the legacy price and save money in the future. To receive real-time alerts on our articles as well as blogs, be sure to check out our profile page and CLICK the orange FOLLOW button . Asides the exclusivities, this article is the truncated version of the research we published in advance to IBI subscribers. Further, you can read up on Dr. Trans background by following this link.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

About this article:ExpandAuthor payment: Seeking Alpha pays for exclusive articles. Payment calculations are based on a combination of coverage area, popularity and quality.Tagged: Investing Ideas, Long Ideas, Healthcare, Biotechnology, SwitzerlandWant to share your opinion on this article? Add a comment.Disagree with this article? Submit your own.To report a factual error in this article, click here

Top 10 Medical Stocks To Own For 2018

5 Lessons From the Life of David Noble

DOL Fiduciary Rule Hurts Now, Annuity Community Says

5 Lessons From the Life of David Noble

(Bloomberg) — The Trump White House and congressional Republicans were at odds Thursday over whether to try for another vote on changing the Affordable Care Act next week, indicating that neither side had a clear strategy for moving on one of the president’s central campaign promises.

A White House aide said President Donald Trump’s administration expects the House to vote soon after lawmakers return from recess on Tuesday, and draft language could be circulated as soon as Thursday night. Success would give the president a legislative victory to boast about before his 100th day in office April 29.

Copyright 2017 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

One Republican said he thinks both about the effects of regulations and his family’s medical history.

Top 10 Medical Stocks To Own For 2018: SPAR Group Inc.(SGRP)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, our Under the Radar Moversnewsletter suggested going long on small cap international merchandising and marketing services stockSPAR Group Inc (NASDAQ: SGRP):

Top 10 Medical Stocks To Own For 2018: HubSpot, Inc.(HUBS)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Cramer was bearish on Ferrellgas Partners (FGP) , Realty Income (O) , Synergy Pharmaceuticals (SGYP) , Avis Budget Group (CAR) and HubSpot (HUBS) .

  • [By Elizabeth Balboa]

    HubSpot Inc (NYSE: HUBS) plummeted nearly 3 percent Tuesday on a new short report by Citron Research, which forecasted a 34-percent near-term decline and a 67-percent long-term fade from $75 to $25.

  • [By Danny Vena]

    There’s another area being driven by AI that may surprise you. The next time you text your bank, cellphone service provider, or retailer, the agent you’re dealing with might be a chatbot. This form of conversational AI is being more widely adopted to perform simple customer service tasks. According to research conducted by marketing technology vendor HubSpot, Inc. (NYSE:HUBS), of 1,426 respondents worldwide, 74% had used voice search in the prior month, and 63% of people using services based on AI technology didn’t even know it.

  • [By Elizabeth Balboa]

    Semiconductors are selling off, and HubSpot Inc (NYSE: HUBS) even earned a Citron short report on its sudden fade.

    “This is rotation station we are in right now and tech is out of favor and value is back in favor,” Dick said.

Top 10 Medical Stocks To Own For 2018: CoreSite Realty Corporation(COR)

Advisors’ Opinion:

  • [By WWW.MONEYSHOW.COM]

    Denver, Colorado-based CoreSite Realty Corporation (COR) offers cloud-enabled, high-performance data center campuses.

    Operating across 17 data centers in eight key North American markets, CoreSite serves a broad range of clients, including telecommunications carriers, media companies, financial and educational institutions, and government agencies.

Top 10 Medical Stocks To Own For 2018: Coherent, Inc.(COHR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Rofin-Sinar Technologies (NASDAQ: RSTI) got a boost, shooting up 37 percent to $31.50 as Coherent, Inc. (NASDAQ: COHR) announced its plans to buy Rofin-Sinar Technologies Inc in a deal valued at around $942 million.

Top 10 Medical Stocks To Own For 2018: Fiserv, Inc.(FISV)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider selling last week:Corcept Therapeutics Inc. (NASDAQ: CORT), Customers Bancorp Inc. (NYSE: CUBI), Ellie Mae Inc. (NYSE: ELLI), Fiserv Inc. (NASDAQ: FISV) and Ulta Beauty Inc. (NASDAQ: ULTA).

Top 10 Medical Stocks To Own For 2018: Safe Bulkers Inc(SB)

Advisors’ Opinion:

  • [By Elizabeth Balboa]

    Meanwhile, Safe Bulkers, Inc. (NYSE: SB) rose $0.73 throughout the 2016, Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) fell $1.69 and Navios Maritime Partners L.P. (NYSE: NMM) dropped $0.93.

  • [By Ben Levisohn]

    StarBulk Carriers (SBLK) and Safe Bulkers (SB) have more than tripled during the past 12 months, while Golden Ocean Group (GOGL) has more than doubled. So it must be time for an upgrade right?

Top 10 Medical Stocks To Own For 2018: Prism Technologies Group, Inc.(PRZM)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of TOWERVIEW LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=TOWERVIEW+LLC

    These are the top 5 holdings of TOWERVIEW LLCTejon Ranch Co (TRC) – 2,795,000 shares, 28.55% of the total portfolio. Saga Communications Inc (SGA) – 1,196,723 shares, 28.51% of the total portfolio. Shares reduced by 1.22%Barnes & Noble Inc (BKS) – 2,375,000 shares, 10.25% of the total portfolio. Corning Inc (GLW) – 600,000 shares, 7.56% of the total portfolio. Barnes & Noble Education Inc

  • [By WWW.GURUFOCUS.COM]

    For the details of TOWERVIEW LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=TOWERVIEW+LLC

    These are the top 5 holdings of TOWERVIEW LLCTejon Ranch Co (TRC) – 2,795,000 shares, 28.55% of the total portfolio. Saga Communications Inc (SGA) – 1,196,723 shares, 28.51% of the total portfolio. Shares reduced by 1.22%Barnes & Noble Inc (BKS) – 2,375,000 shares, 10.25% of the total portfolio. Corning Inc (GLW) – 600,000 shares, 7.56% of the total portfolio. Barnes & Noble Education Inc

Top 10 Medical Stocks To Own For 2018: Ducommun Incorporated(DCO)

Advisors’ Opinion:

  • [By Lee Jackson]

    These companies also reported insider buying last week: Cidara Therapeutics Inc. (NASDAQ: CDTX), Ducommun Inc. (NYSE: DCO), HealthEquity Inc. (NASDAQ: HQY), Panhandle Oil and Gas Inc. (NYSE: PHX) and PolarityTE Inc. (NASDAQ: COOL).

  • [By Lee Jackson]

    These companies also reported insider buying last week: Armour Residential REIT Inc. (NYSE: ARR), Ducommun Inc. (NYSE: DCO), PJT Partners Inc. (NYSE; PJT), Sonic Automotive Inc. (NYSE: SAH)and Tandy Leather Factory Inc. (NASDAQ: TLF).

Top 10 Medical Stocks To Own For 2018: Nektar Therapeutics(NKTR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Nektar Therapeutics (NASDAQ: NKTR) got a boost, shooting up 38 percent to $21.33 after the company reported that it has met its primary and secondary endpoints in Phase 3 Summit-07 study for chronic pain.

  • [By Ben Levisohn]

    Nektar Therapeutics (NKTR) has soared 21% to $18.80 after positive results from a pain-killer trial.

    Tiffany (TIF) has gained 1.6% to $93.90 after getting upgraded to Outperform from Market Perform at William Blair.

  • [By Sean Williams]

    Shares of Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company that utilizes its proprietary intellectual property via licensing deals and through collaborations in the clinical development process to help fight cancer, autoimmune diseases, and chronic pain, surged as much as 20% on Thursday after the company reported its fourth-quarter and full-year results after the closing bell on Wednesday.

Top 10 Medical Stocks To Own For 2018: First NBC Bank Holding Company(FNBC)

Advisors’ Opinion:

  • [By Ben Levisohn]

    The twenty stocks in Worth’s basket are: Ameriprise Financial (AMP) Bank of America, Banner (BANR), Citigroup, Citizens Financial Group (CFG), East West Bancorp (EWBC), First NBC Bank Holding (FNBC), HFF (HF), KeyCorp(KEY), Legacy Texas Financial Group (LTXB), Lincoln National (LNC), Morgan Stanley, Old National Bancorp (ONB), PacWest Bancorp (PACW), PNC Financial Services Group (PNC), Principal Financial Group (PFG), Stifel Financial (SF), SVB Financial Group (SIVB), TCF Financial (TCB), and Wells Fargo.

  • [By Lisa Levin]

    First NBC Bank Holding Company (NASDAQ: FNBC) shares dropped 91 percent to $0.250. First NBC Bank was closed by the Louisiana Office of Financial Institutions.

the best stocks to invest in

13 Best & Worst Broker-Dealers: Q3 Earnings, 2017

5 Annuity Business Beauty Secrets

3 Economic Scenarios for Investors to Watch in Next 5 Years

All eyes will be on the Senate after the Thanksgiving break as the lawmakers will vote on—and likely pass—the Senate Finance Committee’s tax reform bill. The task “is prodigious and the timeline is fast,” says political watcher Andy Friedman in his latest white paper, released Nov. 20.

When Congress last reformed the tax code, “the legislative process took over two years. Now Congress is attempting the same feat in a little over one month,” Friedman of The Washington Update said.

As it stands now, the House has passed its version of the tax reform bill, with a Senate vote expected the week of Nov. 27.

Next steps? “Assuming Senate passage, a ‘conference committee’ comprised of leaders from the two bodies will iron out the many differences between the bills. The single bill that comes out of that committee will go back to the House and Senate again for passage,” then the final version will go to President Donald Trump for his signature.

the best stocks to invest in: Oceaneering International, Inc.(OII)

Advisors’ Opinion:

  • [By Lisa Levin]

    On Friday, energy shares surged by 2.60 percent. Top gainers in the sector included Oceaneering International (NYSE: OII), Willbros Group Inc (NYSE: WG), and Cobalt International Energy, Inc. (NYSE: CIE).

  • [By Monica Gerson]

    Oceaneering International (NYSE: OII) is projected to post its quarterly earnings at $0.35 per share on revenue of $641.85 million.

    Tennant Company (NYSE: TNC) is estimated to report its quarterly earnings at $0.25 per share on revenue of $180.93 million.

the best stocks to invest in: Nektar Therapeutics(NKTR)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Nektar Therapeutics (NKTR) has soared 21% to $18.80 after positive results from a pain-killer trial.

    Tiffany (TIF) has gained 1.6% to $93.90 after getting upgraded to Outperform from Market Perform at William Blair.

  • [By Sean Williams]

    Shares of Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company that utilizes its proprietary intellectual property via licensing deals and through collaborations in the clinical development process to help fight cancer, autoimmune diseases, and chronic pain, surged as much as 20% on Thursday after the company reported its fourth-quarter and full-year results after the closing bell on Wednesday.

  • [By Todd Campbell]

    Nektar Therapeutics (NASDAQ:NKTR) is an intriguing commercial-stage biotech company that’s just reported positive late-stage trial results for its pain-busting drug NKTR-181. However, shares have jumped on the news, and the company’s market cap has swollen to more than $3 billion. Is there more running room left for its investors?

the best stocks to invest in: KLA-Tencor Corporation(KLAC)

Advisors’ Opinion:

  • [By Jim Cramer]

    After a year of stock price fluctuations, the net result is that KLAC’s price has not changed very much. Although its weak earnings growth may have played a role in this flat result, don’t lose sight of the fact that the performance of the overall market, as measured by the S&P 500 Index, was essentially similar. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.

     

  • [By Jim Cramer]

    The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Semiconductors & Semiconductor Equipment industry. The net income increased by 45.2% when compared to the same quarter one year prior, rising from $72.23 million to $104.90 million.

     

  • [By Jim Cramer]

    The debt-to-equity ratio is very high at 10.70 and currently higher than the industry average, implying increased risk associated with the management of debt levels within the company. Despite the company’s weak debt-to-equity ratio, the company has managed to keep a very strong quick ratio of 3.00, which shows the ability to cover short-term cash needs.

     

the best stocks to invest in: Petroleo Brasileiro S.A.- Petrobras(PBR)

Advisors’ Opinion:

  • [By Money Morning News Team]

    Petroleo Brasileira SA Petrobras (NYSE ADR: PBR) is Brazil’s largest oil company and it’s our seventh best oil stock of 2016. Petrobras is an oil and natural gas exploration and production firm. It is also an operator of oil tankers, pipelines, and terminals in South America and globally.

  • [By Chris Lange]

    And Petroleo Brasileiro S.A. (NYSE: PBR), better known as Petrobras, is scheduled to release its most recent quarterly results Tuesday. The consensus estimates call for a net loss of $0.05 per share, as well as $18.05 million in revenue. Shares ended the weekat $8.91. The consensus price target is $11.22, and the 52-week range is $4.98 to $12.56.

  • [By Chris Lange]

    Short interest at Petroleo Brasileiro S.A. (NYSE: PBR), or Petrobras, decreased to 42.63 million shares from the previous 43.53 million. The stock traded at $9.06 a share, in a 52-week range of $5.19 to $12.56. Unfortunately, Petrobras may be trading on an entirely different set of fundamentals and sentiment due to its ongoing woes in Brazil.

  • [By Paul Ausick]

    Credit rating agency Standard & Poor’s on Friday raised its corporate credit rating on Petroleo Brasileiro S.A. (NYSE: PBR), commonly known as Petrobras, one notch, from B+ to BB-. The rating change does not lift Petrobras out of the non-investment grade category, but it lowers the risk from “highly speculative” to “speculative.”

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    Petroleo Brasileiro S.A.- Petrobras (NYSE: PBR): Free Stock Analysis Report
     
    Bill Barrett Corporation (NYSE: BBG): Free Stock Analysis Report
     
    Northern Oil and Gas, Inc. (AMEX:NOG): Free Stock Analysis Report
     
    Rice Midstream Partners LP (NYSE: RMP): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research

  • [By Chris Lange]

    And Petroleo Brasileiro S.A. (NYSE: PBR), better known as Petrobras, is scheduled to release its most recent quarterly results late Thursday. The consensus estimates call for a profit of $0.16 per share, as well as $23.81 billion in revenue. Shares ended the weekat $8.86. The consensus price target is $10.82, and the 52-week range is $7.61 to $12.56.

Best Undervalued Stocks To Own For 2018

Nearly every traditional valuation measure says the S&P 500 is currently expensive.

Which means if you’re a value investor trying to make money in today’s market, you’ll need to try harder.

To do that, you need to start looking in areas where most of the investment world isn’t.

Here’s my idea…

Howard Hughes Corporation Underfollowed and Undervalued

Howard Hughes (HHC) has a unique business model for a publicly traded company.

This company isn’t a REIT.This company isn’t a homebuilder.And this company isn’t a land developer.

Instead it’s all three of these things.

And as a result, it doesn’t fit into any of Wall Street’s existing boxes.

You see, Wall Street has analysts assigned to each individual sector but no analysts assigned to cover all three. Which means that there are currently only a handful of analysts covering HHC.

Which today offers an extremely compelling value proposition…

Best Undervalued Stocks To Own For 2018: Nektar Therapeutics(NKTR)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Nektar Therapeutics (NKTR) has soared 21% to $18.80 after positive results from a pain-killer trial.

    Tiffany (TIF) has gained 1.6% to $93.90 after getting upgraded to Outperform from Market Perform at William Blair.

  • [By Sean Williams]

    Shares of Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company that utilizes its proprietary intellectual property via licensing deals and through collaborations in the clinical development process to help fight cancer, autoimmune diseases, and chronic pain, surged as much as 20% on Thursday after the company reported its fourth-quarter and full-year results after the closing bell on Wednesday.

  • [By Lisa Levin]

    Shares of Nektar Therapeutics (NASDAQ: NKTR) got a boost, shooting up 38 percent to $21.33 after the company reported that it has met its primary and secondary endpoints in Phase 3 Summit-07 study for chronic pain.

  • [By Todd Campbell]

    Nektar Therapeutics (NASDAQ:NKTR) is an intriguing commercial-stage biotech company that’s just reported positive late-stage trial results for its pain-busting drug NKTR-181. However, shares have jumped on the news, and the company’s market cap has swollen to more than $3 billion. Is there more running room left for its investors?

Best Undervalued Stocks To Own For 2018: Delcath Systems Inc.(DCTH)

Advisors’ Opinion:

  • [By Paul Ausick]

    Delcath Systems Inc. (NASDAQ: DCTH) dropped nearly 44% Friday to post a new 52-week low of $0.46 after closing Thursday at $0.82. The 52-week high is $8.80. Volume of around 4.5 million was more than 20 times the daily average of around 280,000 shares traded. The company had no specific news.

  • [By Money Morning News Team]

    If you’re looking for proof of just how explosively profitable penny stocks are, Delcath Systems Inc. (Nasdaq: DCTH) is a perfect piece of evidence. This company saw its stock price surge from $0.02 on June 1 to $0.19 on June 26. That marked a stunning 850% gain, which happened after the company announced phase 2 trial data for its cancer drug Melphalan would be released.

Best Undervalued Stocks To Own For 2018: Chipotle Mexican Grill Inc.(CMG)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows El Pollo LoCo Holdings having fallen below its IPO price for retail investors, butsharesappear to have stabilized over the past year and a halfwhile potentialpeers like small capFiesta Restaurant Group Inc (NASDAQ: FRGI) and large cap Chipotle Mexican Grill, Inc (NYSE: CMG) have performed better in the past and small cap Chuy’s Holdings Inc (NASDAQ: CHUY) is moving sideways:

  • [By Mike Turner]

    Turner pick Chipotle Mexican Grill(CMG) as his entry into the Best Stocks competition. Chipotle certainly has been one of the best stocks to buy in years past; CMG stock has earned a return of 930% in the past decade, beating the S&P 500’s 105% return by more than a little bit.

    Brushing off the recent supply problems that resulted in dozens of customers getting sick from E. coli, Turner believes the stock can return to the $700 range when the business recovers from its current rough patch. 

  • [By Rick Munarriz]

    Just when you thought that a return to positive comps would spell an end to the giveaways thatChipotle Mexican Grill(NYSE:CMG)sprinkled through 2016, the former fast-casual darling is back with another online game where everybody’s a winner.

  • [By WWW.THESTREET.COM]

    Chipotle Mexican Grill (CMG) : “This is not on my to do list right now.”

    On Real Money, Cramer looks at which retailers are doing better — and better yet, which offer investment opportunities. Get his insights with a free trial subscription to Real Money.

  • [By Ben Levisohn]

    Chipotle Mexican Grill (CMG) has fallen 1.4% to $405.20 after JPMorgan cut its rating to Neutral from Overweight.

    Tiffany (TIF) has tumbled 4.7% after its holiday sales were lower than it had expected. It blamed, in part, disruptions created by the nearby Trump Towers.

  • [By Peter Graham]

    A long term performance chart shows Del Taco Restaurants now outperforming Mexican restaurant stock peers such as mid cap Chipotle Mexican Grill, Inc (NYSE: CMG) and small caps El Pollo LoCo Holdings Inc (NASDAQ: LOCO), Fiesta Restaurant Group Inc (NASDAQ: FRGI) and Chuy’s Holdings Inc (NASDAQ: CHUY) have mostly been drifting lower lately:

Best Undervalued Stocks To Own For 2018: Orion Marine Group Inc(ORN)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows small caps Great Lakes Dredge & Dock Corporation andLayne Christensen Company (NASDAQ: LAYN) underperforming, but possibly recovering while Orion Group Holdings (NYSE: ORN) had a clear reversal early last year:

Best Undervalued Stocks To Own For 2018: Vanguard Mega Cap Growth ETF (MGK)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    Three of Vanguard's mega-cap equity ETFs now sport annual expense ratios of 0.07 percent, down from 0.09 percent. Those ETFs are the Vanguard Mega Cap ETF (NYSE: MGC), Vanguard Mega Cap 300 Growth Index ETF (NYSE: MGK) and the Vanguard Mega Cap Value Index ETF (NYSE: MGV).